Sign Up for Our Newsletter!

Stay connected with ZERO Prostate Cancer through our newsletter below:

Name

Xtandi Granted Priority Review for Prostate Cancer Treatment

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

Read more.


Source: CURE Magazine

Share